Adamas Pharmaceuticals

Adamas Pharmaceuticals discovers and develops therapies to improve the daily lives of people affected by chronic neurologic disorders. The Company pioneered a platform to develop medicines for chronic neurologic disorders, which is built upon its understanding of time-dependent biologic processes responsible for specific disease activities and drug response.

Adamas Pharmaceuticals' lead product candidate, ADS-5102, is a high-dose amantadine therapy in development for the treatment of levodopa-induced dyskinesia in people with Parkinson’s disease. It is also investigating ADS-4101, modified-release lacosamide capsules, for the treatment of partial-onset seizures in patients with epilepsy.

Additionally, Adamas' licensed assets for the treatment of moderate to severe Alzheimer’s disease, Namenda XR® extended-release capsules, and Namzaric® capsules, are currently marketed by Allergan.

Company Growth (employees)
Type
Public
HQ
Emeryville, US
Founded
2002
Size (employees)
73 (est)+6%
Adamas Pharmaceuticals was founded in 2002 and is headquartered in Emeryville, US

Key People at Adamas Pharmaceuticals

Gregory Went

Gregory Went

Chief Executive Officer & Chairman
Alf Merriweather

Alf Merriweather

Chief Financial Officer
David Mahoney

David Mahoney

Director

Adamas Pharmaceuticals Office Locations

Adamas Pharmaceuticals has an office in Emeryville
Emeryville, US (HQ)
750 1900 Powell St

Adamas Pharmaceuticals Data and Metrics

Adamas Pharmaceuticals Financial Metrics

Adamas Pharmaceuticals's revenue was reported to be $0 in Q1, 2017
USD

Net income (Q1, 2017)

(16 m)

EBIT (Q1, 2017)

(16.2 m)

Market capitalization (17-Aug-2017)

313.9 m

Cash (31-Mar-2017)

20.9 m
Adamas Pharmaceuticals's current market capitalization is $313.9 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

55.8 m1.9 m572 k

Revenue growth, %

(97%)(70%)

R&D expense

21.9 m35.9 m31.2 m

General and administrative expense

15.5 m23.5 m

Operating expense total

37.3 m59.4 m61.6 m

EBIT

18.5 m(57.4 m)(61 m)

EBIT margin, %

33%(2998%)(10662%)

Interest income

(917 k)363 k811 k

Pre tax profit

17.6 m(57.1 m)(60.2 m)

Income tax expense

(7.4 m)(5.3 m)(115 k)

Net Income

10.2 m(51.8 m)(60.1 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

25.2 m215 k226 k398 k768 k175 k222 k138 k

R&D expense

5.2 m5.4 m7.5 m8.7 m10 m7.5 m9.2 m7.4 m7.1 m

General and administrative expense

3.3 m4.4 m4.9 m5.8 m5.8 m

Operating expense total

8.4 m9.8 m12.5 m14.6 m15.8 m7.5 m9.2 m7.4 m7.1 m

EBIT

16.7 m(9.6 m)(12.2 m)(14.2 m)(15 m)(14 m)(17.1 m)(14.6 m)(16.2 m)

EBIT margin, %

66%(4442%)(5410%)(3556%)(1952%)(7993%)(7685%)(10611%)

Interest income

78 k102 k85 k160 k184 k249 k204 k

Pre tax profit

16.6 m(9.6 m)(12.1 m)(14.1 m)(14.9 m)(13.8 m)(16.9 m)(14.4 m)

Income tax expense

(178 k)(6 k)(54 k)(178 k)(51 k)54 k

Net Income

16.4 m(9.6 m)(12.2 m)(14.1 m)(14.9 m)(13.8 m)(16.9 m)(14.4 m)(16 m)
USDFY, 2014FY, 2015FY, 2016

Cash

61.4 m33.1 m23.7 m

Accounts Receivable

524 k1.3 m794 k

Inventories

645 k5.1 m2.5 m

Current Assets

123.5 m113.2 m117 m

PP&E

1.2 m2.4 m3.2 m

Total Assets

161.2 m128.7 m142.5 m

Accounts Payable

3.7 m3.1 m3.6 m

Current Liabilities

12.5 m11.8 m9.7 m

Non-Current Liabilities

749 k547 k

Total Liabilities

12.6 m10.3 m

Additional Paid-in Capital

157.6 m178.5 m254.6 m

Retained Earnings

(10.3 m)(62.2 m)(122.2 m)

Total Equity

147.1 m116.2 m132.2 m

Financial Leverage

1.1 x1.1 x1.1 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

144.6 m137.5 m29.2 m37.9 m37.1 m98.4 m109.3 m9.8 m20.9 m

Accounts Receivable

218 k120 k485 k361 k936 k461 k860 k769 k1.7 m

Current Assets

145.8 m138.9 m115.5 m126.4 m105.5 m169.6 m163.3 m110.4 m115.2 m

PP&E

336 k443 k1.3 m2 m2.1 m2.9 m3.4 m3.1 m3.1 m

Total Assets

146.2 m139.4 m147.3 m147.1 m136.8 m178.5 m168.6 m157.2 m128.5 m

Accounts Payable

3.3 m3 m3.8 m3.9 m2.9 m3.5 m4.7 m6 m3 m

Current Liabilities

6 m6.7 m8.1 m10 m11 m10.7 m12.8 m12.6 m8.3 m

Non-Current Liabilities

8 k1.7 m1.9 m1.8 m699 k649 k600 k492 k

Additional Paid-in Capital

150.7 m152.8 m160.1 m171.7 m175.4 m243 m248 m251.4 m258.1 m

Retained Earnings

(10.5 m)(20.1 m)(22.6 m)(36.6 m)(51.5 m)(76 m)(92.9 m)(107.2 m)(138.2 m)

Total Equity

140.2 m132.7 m137.6 m135.1 m124 m167.1 m155.2 m144.1 m119.7 m

Financial Leverage

1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x
USDFY, 2014FY, 2015FY, 2016

Net Income

10.2 m(51.8 m)(60.1 m)

Depreciation and Amortization

155 k435 k808 k

Accounts Receivable

(395 k)(760 k)490 k

Inventories

(97.8 m)(153.7 m)2.1 m

Accounts Payable

1.5 m(788 k)502 k

Cash From Operating Activities

(24.2 m)(28.3 m)(48.1 m)

Purchases of PP&E

(1.3 m)(1.4 m)(1.6 m)

Cash From Investing Activities

(97.4 m)8.1 m(26.7 m)

Cash From Financing Activities

47 m10.8 m65.4 m

Interest Paid

279 k279 k

Income Taxes Paid

341 k4.7 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

16.4 m(9.6 m)(12.2 m)(14.1 m)(14.9 m)(13.8 m)(16.9 m)(14.4 m)(16 m)

Accounts Receivable

218 k120 k485 k361 k936 k461 k860 k769 k1.7 m

Accounts Payable

3.3 m3 m3.8 m3.9 m2.9 m3.5 m4.7 m6 m3 m
Y, 2017

Financial Leverage

1.1 x

Adamas Pharmaceuticals Market Value History

Traffic Overview of Adamas Pharmaceuticals

Adamas Pharmaceuticals Company Life and Culture

You may also be interested in